Michael Foutz, MD
Family Medicine · Kuna, IDNPI 1992782361
Payments from drug & device makers
Across 14 payments — averaging $122.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lucid Diagnostics Inc.$2K
- Boston Scientific$57
- Dexcom, Inc.$27
- AbbVie$27
- Stryker$25
- Phadia US Inc.$22
- plus $12 from 1 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lucid Diagnostics Inc.$500
What the payments were for
- Speaking & faculty fees$1,50087%
- Food & beverage$21613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lucid Diagnostics Inc. | 8 | $1,545 |
| Boston Scientific | 1 | $57 |
| Dexcom, Inc. | 1 | $27 |
| AbbVie | 1 | $27 |
| Stryker | 1 | $25 |
| Phadia US Inc. | 1 | $22 |
| Bardy Diagnostics, Inc. | 1 | $12 |
How this compares
$1,716 in reported general payments places this provider in the 80th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $83,401 |
| EliquisApixaban | 68 | $68,933 |
| JardianceEmpagliflozin | 39 | $39,200 |
| JanuviaSitagliptin Phosphate | 35 | $35,526 |
| MounjaroTirzepatide | 19 | $28,461 |
| XareltoRivaroxaban | 19 | $20,059 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $11,013 |
| MyrbetriqMirabegron | 16 | $10,671 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,298 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $8,670 |
| Paliperidone ErPaliperidone | 12 | $6,613 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 158 | $6,409 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,724 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,104 |
| Levothyroxine Sodium | 465 | $4,687 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Kuna
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.